Colon Cancer Diagnosis and Therapy
Springer International Publishing (Verlag)
978-3-030-63368-4 (ISBN)
Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.
This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.
Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and PhD, both in Biotechnology from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his D.Sc. from Berhampur University in Berhampur, Odisha, India. Nagaraju's research focuses on translational research in gastrointestinal malignancies. He has published over 100 research papers in highly respected international journals and has presented more than 50 abstracts at various national and international conferences. He is the author and editor of several books. Dr. Nagaraju is an editorial board member of several internationally recognized academic journals, and is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is a member of the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), the Science Advisory Board, The RNA Society and the American Association of Cancer Research (AACR). Dr. Dhananjay Shukla is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Shukla received his PhD in Biotechnology from Defense Institute of Physiology and Allied Science, New Delhi, India. Dr. Shukla has expertise in cancer physiology and has published more than 25 research papers in various highly reputed international journal. He has presented and been invited to lecture at a number national and international conferences. Dr. Naveen Kumar Vishvakarma is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Vishvakarma received his PhD in Biotechnology from Banaras Hindu University, Varanasi, India. He has published more than 20 research papers in highly reputed journals on various aspects of cancer biology. He has written a number of book chapters for international publishers and presented abstract at national and international conferences.
2.Colorectal cancer: A model for the study of cancer immunology3.Impact of Covid-19 Pandemic on Gastro Intestinal Cancer Patients: An Emphasis on Colorectal Cancer
4. Potential role of NMR and MRI in colon cancer
5.Role of micro-RNA in-situ hybridization in colon cancer diagnosis
6.Role of epigenetics in colorectal cancer
7.Exosomal biomarkers in colorectal cancer
8.Biomarkers as putative therapeutic targets in colorectal cancer
9. Proteins involved in colorectal cancer: Identification strategies and possible roles
10. Short-chain fatty acids as therapeutic agents in colon malignancies
11. Targeting of angiogenesis for colorectal cancer therapy
12. Anti-inflammatory molecular mechanism and contribution of drug transport molecules in colorectal cancer cells
13. Emerging role of circulating tumour DNA in treatment response prognosis in colon cancer
14. Immuno-modulating mediators of colon cancer as immunotherapeutic: mechanism and potential15. Immune checkpoint inhibitors as armor for targeted immunotherapy of colorectal cancer16. Examining the role of the MACC1 gene in colorectal cancer metastasisIndex
| Erscheinungsdatum | 12.07.2021 |
|---|---|
| Zusatzinfo | XII, 369 p. 20 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 695 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
| Schlagworte | angiogenesis • Biomarkers • cancer mortalities • circulating tumor DNA • CRC • diagnosis and screening • drug resistance • epidemiology • exosomal biomarkers • immunotherapy • Metastasis • micro-RNA • MRI • nanomedicine • nanotechnology • NMR • Survival rate • targeted therapy • Therapeutic Strategies • transcription factors |
| ISBN-10 | 3-030-63368-3 / 3030633683 |
| ISBN-13 | 978-3-030-63368-4 / 9783030633684 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
